GH Research PLC is preparing to present data from its GH001-TRD-201 and GH001-BD-202 clinical trials at the 39th European College of Neuropsychopharmacology (ECNP) annual meeting. Scheduled for October 10-13, 2026, in Munich, Germany, this event is significant for the company as it highlights its ongoing research in the treatment of depression.
The data will be showcased in three posters during Poster Session 2 on October 11, 2026, presented by notable experts including Prof. Wiesław J. Cubała, Prof. Bernhard T. Baune, and Dr. Max de Leeuw. This presentation is expected to attract attention within the pharmaceutical preparations sector, particularly among stakeholders focused on mental health.
In addition to the poster presentations, GH Research will sponsor an industry satellite symposium titled “Achieving remission in treatment-resistant depression: current evidence and research on rapid-acting antidepressants” on October 10, 2026. This symposium aims to foster discussion on the latest advancements and evidence in treating depression, particularly for patients who have not responded to traditional therapies.
GH Research PLC, based in Dublin, Ireland, is classified under the SIC code 2834, which pertains to pharmaceutical preparations. This classification places it in direct competition with other companies in the pharmaceutical industry that are also developing treatments for mental health conditions.
The recent filing, accession number 0001140361-26-039191, indicates that the company is actively engaging with the scientific community and positioning itself as a key player in the evolving landscape of mental health treatments.
It remains to be seen how the data presented at ECNP will be received by the industry and what implications it may have for future research and development efforts in the field.